PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.01
D/E less than half of AVXL's 11.11. Charlie Munger would verify if this conservative approach provides competitive advantages.
6.24
Dangerously higher net debt above 1.5x AVXL's 2.24. Jim Chanos would check for potential debt spiral risks.
-1373.41
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
5.52
Current ratio 1.25-1.5x AVXL's 4.97. Mohnish Pabrai would examine if this strength creates buying power advantages.
No Data
No Data available this quarter, please select a different quarter.